Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Sällberg M[au]:

Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. Lybeck C et al. Eur J Gastroenterol Hepatol. (2019)

Editorial: HBV-the naked truth? Pasetto A et al. Aliment Pharmacol Ther. (2019)

Prospects and progress of DNA vaccines for treating hepatitis B. Chen M et al. Expert Rev Vaccines. (2016)

Search results

Items: 1 to 50 of 157

1.

Editorial: HBV-the naked truth?

Pasetto A, Ahlén G, Sällberg M.

Aliment Pharmacol Ther. 2019 Oct;50(8):963-964. doi: 10.1111/apt.15428. No abstract available.

PMID:
31591767
2.

Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.

Söderholm J, Yilmaz A, Svenningsson A, Büsch K, Wejstål R, Brolund A, Kövamees J, Sällberg M, Lagging M, Gisslén M.

J Neurol. 2019 Sep;266(9):2208-2215. doi: 10.1007/s00415-019-09397-8. Epub 2019 May 31.

3.

Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.

Lybeck C, Brenndörfer ED, Sällberg M, Montgomery SM, Aleman S, Duberg AS.

Eur J Gastroenterol Hepatol. 2019 Apr;31(4):506-513. doi: 10.1097/MEG.0000000000001316.

4.

Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers.

Psaros Einberg A, Brenndörfer ED, Frelin L, Hallberg L, Sällberg M, Fischler B.

J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):106-111. doi: 10.1097/MPG.0000000000001755.

PMID:
28953534
5.

Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C.

Psaros Einberg A, Duberg AS, Filipovich O, Nyström J, Zhirkov A, Brenndörfer ED, Frelin L, Rukoiatkina E, Lobzin Y, Sällberg M, Fischler B, Lutckii A.

J Pediatr Gastroenterol Nutr. 2017 Dec;65(6):608-612. doi: 10.1097/MPG.0000000000001711.

PMID:
28820758
6.

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.

Levander S, Holmström F, Frelin L, Ahlén G, Rupp D, Long G, Bartenschlager R, Sällberg M.

Gut. 2018 Aug;67(8):1525-1535. doi: 10.1136/gutjnl-2016-313579. Epub 2017 Jun 23.

7.

Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Balasiddaiah A, Davanian H, Aleman S, Pasetto A, Frelin L, Sällberg M, Lohmann V, Koh S, Bertoletti A, Chen M.

J Virol. 2017 Apr 13;91(9). pii: e00010-17. doi: 10.1128/JVI.00010-17. Print 2017 May 1.

8.

Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature.

Davanian H, Balasiddaiah A, Heymann R, Sundström M, Redenström P, Silfverberg M, Brodin D, Sällberg M, Lindskog S, Kruger Weiner C, Chen M.

Oncotarget. 2017 Jan 17;8(3):4530-4542. doi: 10.18632/oncotarget.13889.

9.

Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Holmström F, Chen M, Balasiddaiah A, Sällberg M, Ahlén G, Frelin L.

Sci Rep. 2016 May 4;6:24991. doi: 10.1038/srep24991.

10.

A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines.

Levander S, Sällberg M, Ahlén G, Frelin L.

Vaccine. 2016 May 27;34(25):2821-33. doi: 10.1016/j.vaccine.2016.04.030. Epub 2016 Apr 22.

11.

A targeted controlled force injection of genetic material in vivo.

Ahlén G, Frelin L, Holmström F, Smetham G, Augustyn S, Sällberg M.

Mol Ther Methods Clin Dev. 2016 Mar 30;5:16016. doi: 10.1038/mtm.2016.16. eCollection 2016.

12.

Prospects and progress of DNA vaccines for treating hepatitis B.

Chen M, Jagya N, Bansal R, Frelin L, Sällberg M.

Expert Rev Vaccines. 2016 May;15(5):629-40. doi: 10.1586/14760584.2016.1131615. Epub 2016 Jan 28. Review.

PMID:
26652035
13.

Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo.

Bansal R, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sällberg M.

PLoS One. 2015 Jun 1;10(6):e0128466. doi: 10.1371/journal.pone.0128466. eCollection 2015.

14.

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Hedenstierna M, Weiland O, Brass A, Bankwitz D, Behrendt P, Uhnoo I, Aleman S, Cardell K, Fryden A, Norkrans G, Eilard A, Glaumann H, Pietschmann T, Sällberg M, Brenndörfer ED.

Aliment Pharmacol Ther. 2015 Mar;41(6):532-43. doi: 10.1111/apt.13096. Epub 2015 Jan 28.

15.

Electroporation for therapeutic DNA vaccination in patients.

Sällberg M, Frelin L, Ahlén G, Sällberg-Chen M.

Med Microbiol Immunol. 2015 Feb;204(1):131-5. doi: 10.1007/s00430-014-0384-8. Epub 2014 Dec 23. Review.

PMID:
25535102
16.

Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination.

Brass A, Frelin L, Milich DR, Sällberg M, Ahlén G.

Mol Ther. 2015 Mar;23(3):578-90. doi: 10.1038/mt.2014.233. Epub 2014 Dec 10.

17.

Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.

Brenndörfer ED, Brass A, Karthe J, Ahlén G, Bode JG, Sällberg M.

J Immunol. 2014 Feb 15;192(4):1671-80. doi: 10.4049/jimmunol.1301077. Epub 2014 Jan 17.

18.

A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus.

Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A.

Mol Ther Nucleic Acids. 2013 Aug 13;2:e114. doi: 10.1038/mtna.2013.43.

19.

Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C.

Ahlén G, Frelin L, Brenndörfer ED, Brass A, Weiland O, Chen M, Sällberg M.

Drug Resist Updat. 2013 Jul-Nov;16(3-5):60-7. doi: 10.1016/j.drup.2013.06.001. Epub 2013 Aug 2. Review.

20.

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, Inchauspé G, Sällberg M.

J Infect Dis. 2013 Sep;208(6):1008-19. doi: 10.1093/infdis/jit267. Epub 2013 Jun 17.

21.

Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M.

Mol Ther. 2013 Sep;21(9):1796-805. doi: 10.1038/mt.2013.119. Epub 2013 Jun 11.

22.

Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.

Rahbin N, Frelin L, Aleman S, Hultcrantz R, Sällberg M, Brenndörfer ED.

Biochem Biophys Res Commun. 2013 Mar 29;433(1):31-5. doi: 10.1016/j.bbrc.2013.02.075. Epub 2013 Feb 27.

PMID:
23454379
23.

Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy.

Hamsten C, Starkhammar M, Tran TA, Johansson M, Bengtsson U, Ahlén G, Sällberg M, Grönlund H, van Hage M.

Allergy. 2013 Apr;68(4):549-52. doi: 10.1111/all.12128. Epub 2013 Feb 18.

PMID:
23414348
24.

Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models.

Ahlén G, Sällberg M, Frelin L.

Methods Mol Biol. 2013;940:239-67. doi: 10.1007/978-1-62703-110-3_20.

PMID:
23104348
25.

TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M.

J Immunol. 2012 Nov 1;189(9):4510-9. doi: 10.4049/jimmunol.1201613. Epub 2012 Sep 28.

26.

Hepatitis C virus-mediated modulation of cellular immunity.

Brenndörfer ED, Sällberg M.

Arch Immunol Ther Exp (Warsz). 2012 Oct;60(5):315-29. doi: 10.1007/s00005-012-0184-z. Epub 2012 Aug 22. Review.

PMID:
22911132
27.

Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease.

Ahlén G, Chen A, Roe B, Falkeborn T, Frelin L, Hall WW, Sällberg M, Söderholm J.

J Gen Virol. 2012 Aug;93(Pt 8):1680-6. doi: 10.1099/vir.0.043745-0. Epub 2012 May 16.

PMID:
22592266
28.

HIV inhibition by CD4 and CCR5-derived glycopeptides.

Perdomo MF, Sällberg M, Vahlne A.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1052-8. doi: 10.1089/AID.2012.0009. Epub 2012 Jun 12.

PMID:
22559037
29.

Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3.

Pasetto A, Frelin L, Brass A, Yasmeen A, Koh S, Lohmann V, Bartenschlager R, Magalhaes I, Maeurer M, Sällberg M, Chen M.

J Gen Virol. 2012 Feb;93(Pt 2):247-58. doi: 10.1099/vir.0.037903-0. Epub 2011 Nov 9.

30.

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.

Malik IR, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, Frelin L.

Scand J Infect Dis. 2012 Jan;44(1):55-9. doi: 10.3109/00365548.2011.608711. Epub 2011 Sep 21.

PMID:
21933033
31.

Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.

Brenndörfer ED, Brass A, Söderholm J, Frelin L, Aleman S, Bode JG, Sällberg M.

Gut. 2012 Apr;61(4):589-96. doi: 10.1136/gut.2010.232116. Epub 2011 Aug 3.

PMID:
21813471
32.

Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis.

Söderberg C, Marmur J, Eckes K, Glaumann H, Sällberg M, Frelin L, Rosenberg P, Stål P, Hultcrantz R.

APMIS. 2011 Jul;119(7):412-20. doi: 10.1111/j.1600-0463.2011.02746.x. Epub 2011 Apr 25.

PMID:
21635548
33.

Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.

Chen A, Ahlén G, Brenndörfer ED, Brass A, Holmström F, Chen M, Söderholm J, Milich DR, Frelin L, Sällberg M.

J Immunol. 2011 May 1;186(9):5107-18. doi: 10.4049/jimmunol.1001790. Epub 2011 Mar 23.

34.

Cloning and expression of envelope protein of Thai genotype I strain KE-093 of Japanese encephalitis virus.

Witthajitsomboon N, Chen A, Lorroengsil S, Sällberg M, Pantuwatana S.

Southeast Asian J Trop Med Public Health. 2010 Nov;41(6):1359-67.

PMID:
21329311
35.

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Frelin L, Brass A, Ahlén G, Brenndörfer ED, Chen M, Sällberg M.

Drug News Perspect. 2010 Dec;23(10):647-53. doi: 10.1358/dnp.2010.23.10.1513492. Review.

PMID:
21180650
36.

Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.

Brenndörfer ED, Weiland M, Frelin L, Derk E, Ahlén G, Jiao J, Bode JG, Sällberg M.

Hepatology. 2010 Nov;52(5):1553-63. doi: 10.1002/hep.23870.

PMID:
20886569
37.

Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes.

Nyström J, Chen A, Frelin L, Ahlén G, Koh S, Brass A, Peterson DL, Fons M, Milich DR, Hultgren C, Sällberg M.

J Infect Dis. 2010 Jun 15;201(12):1867-79. doi: 10.1086/652808.

PMID:
20446851
38.

Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine.

Gill HS, Söderholm J, Prausnitz MR, Sällberg M.

Gene Ther. 2010 Jun;17(6):811-4. doi: 10.1038/gt.2010.22. Epub 2010 Mar 4.

39.

Effects of HCV proteins in current HCV transgenic models.

Jiao J, Wang J, Sallberg M.

Hepatol Res. 2010 Feb;40(2):115-24. doi: 10.1111/j.1872-034X.2009.00574.x. Epub 2009 Sep 25.

PMID:
19788690
40.

The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo.

Kriegs M, Bürckstümmer T, Himmelsbach K, Bruns M, Frelin L, Ahlén G, Sällberg M, Hildt E.

J Biol Chem. 2009 Oct 9;284(41):28343-51. doi: 10.1074/jbc.M109.038877. Epub 2009 Aug 12.

41.

DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target.

Sällberg M, Frelin L, Weiland O.

Expert Opin Biol Ther. 2009 Jul;9(7):805-15. doi: 10.1517/14712590902988444. Review.

PMID:
19527105
42.

Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase.

Brenndörfer ED, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, Hengel H, Bartenschlager R, Sällberg M, Häussinger D, Bode JG.

Hepatology. 2009 Jun;49(6):1810-20. doi: 10.1002/hep.22857.

PMID:
19475692
43.

Interaction of the hepatitis B core antigen and the innate immune system.

Lee BO, Tucker A, Frelin L, Sallberg M, Jones J, Peters C, Hughes J, Whitacre D, Darsow B, Peterson DL, Milich DR.

J Immunol. 2009 Jun 1;182(11):6670-81. doi: 10.4049/jimmunol.0803683.

44.

A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans.

Frelin L, Sällberg M.

Genome Med. 2009 Jan 23;1(1):15. doi: 10.1186/gm15.

45.

Oral viral infections of children.

Sällberg M.

Periodontol 2000. 2009 Feb;49:87-95. doi: 10.1111/j.1600-0757.2008.00277.x. Review. No abstract available.

PMID:
19152527
46.

Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine.

Nyström J, Cardell K, Björnsdottir TB, Fryden A, Hultgren C, Sällberg M.

Vaccine. 2008 Nov 5;26(47):5967-72. doi: 10.1016/j.vaccine.2008.08.054. Epub 2008 Sep 17.

PMID:
18804140
47.

Neutralization of HIV-1 by redirection of natural antibodies.

Perdomo MF, Levi M, Sällberg M, Vahlne A.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12515-20. doi: 10.1073/pnas.0805777105. Epub 2008 Aug 21.

48.

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Ahlén G, Derk E, Weiland M, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grandér D, Frelin L, Sällberg M.

Gut. 2009 Apr;58(4):560-9. doi: 10.1136/gut.2007.147264. Epub 2008 Aug 8.

49.

Genetic differences of E gene of a Thai strain of Japanese encephalitis virus that determine small plaque size phenotype but not neurovirulence in suckling mice.

Lorroengsil S, Chen A, Sällberg M, Pantuwatana S.

Southeast Asian J Trop Med Public Health. 2008 May;39(3):387-93.

PMID:
18564676
50.

Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine.

Cardell K, Akerlind B, Sällberg M, Frydén A.

J Infect Dis. 2008 Aug 1;198(3):299-304. doi: 10.1086/589722.

PMID:
18544037

Supplemental Content

Loading ...
Support Center